

Utility of A1C for Diabetes Screening in the 1999–2004 NHANES Population

CATHERINE BUELL, MD^{*1,2}
 DUCLIE KERMAH, MPH¹
 MAYER B. DAVIDSON, MD¹

Thirty percent of people with diabetes are undiagnosed (1), and up to 25% already have microvascular complications at diagnosis (2). The American Diabetes Association recommends screening adults ≥ 45 years of age, especially those with a BMI ≥ 25 kg/m², at 3-year intervals with a fasting plasma glucose (FPG) measurement (3). However, physicians infrequently use an FPG for screening. For example, in a large health maintenance organization within the University of Michigan health system, 184 physicians at 22 separate locations screened 5,752 (69%) of 8,286 people without diabetes over a 3-year period. Ninety-five percent of the screening tests were random glucose measurements, 3% were FPGs, and 2% were A1Cs (4). Random glucose levels depend on the length of time after the previous meal and the carbohydrate content of that meal. There is no agreement on what random glucose values should lead to further investigations.

Because A1C levels reflect average glycemia during the preceding 3–4 months, meal issues are not a factor. To determine what A1C level should lead to further tests to diagnose diabetes, we examined the 1999–2004 National Health and Nutrition Examination Survey (NHANES) population of those not known to have diabetes to determine the sensitivity and specificity with which various A1C levels identified people with diabetes.

RESEARCH DESIGN AND METHODS

NHANES oversampled African-American and Hispanic individuals to obtain enough data for analysis in this minority subset. Accordingly, results were weighted to reflect the U.S. population. SUDAAN statistical software was used to obtain weighted estimates that account for the complex survey design of NHANES (5). Of the 8,881 subjects with a 6-year weighting variable identified, 6,036 were 20 years of age or older and 6,012 had fasting blood samples drawn. Glycated hemoglobin levels were measured by a boronate affinity high-performance liquid chromatography (HPLC) system and converted to A1C levels (6). The normal range was 4.0–6.0% (personal communication, Randie Little, PhD, University of Missouri School of Medicine, Columbia, MO). Subjects were queried by questionnaire, and 532 were excluded because of a previous diagnosis of diabetes. An additional 535 subjects were excluded due to missing questionnaire data and 10 for missing laboratory data. The final dataset included 4,935 individuals. Those whose FPG concentrations were ≥ 126 mg/dl were diagnosed with diabetes. The results were analyzed by a receiver operating characteristic (ROC) curve.

RESULTS — Of the final cohort of 4,935 subjects, 3,280 were normal (FPG < 100 mg/dl), 1,485 had impaired fasting

glucose (FPG 100–125 mg/dl), and 170 had previously undiagnosed diabetes (FPG ≥ 126 mg/dl). The relationship between A1C level and diagnosis of diabetes is shown in Fig. 1. An A1C level of 5.8% yielded the highest combination of sensitivity (86%) and specificity (92%) in the total population. Analyses of subsets of these NHANES subjects revealed sensitivities of 84, 90, 84, 93, and 95% in 2,334 men, 2,601 women, 2,631 non-Hispanic whites, 874 African Americans, and 1,295 Hispanics, respectively. Specificities were 92, 92, 93, 86, and 91%, respectively. The 135 subjects who listed their race as “other” were not analyzed separately because of their small number.

CONCLUSIONS — The American Diabetes Association recommends confirmation of an FPG level to diagnose diabetes (3). Requiring confirmation (not available in NHANES data) would decrease sensitivity and increase specificity. However, an A1C level of 5.8% is consistent with the results of a previous ROC analysis on the 1988–1994 NHANES III population utilizing an ion exchange HPLC A1C assay (normal $5.17 \pm 0.45\%$ [SD]) with diabetes also diagnosed by an FPG ≥ 126 mg/dl. They concluded that the best screening value lay between 1 and 2 SDs above the mean (7). The two NHANES studies relate A1C levels to the prevalence of diabetes. Two studies have related A1C levels to the incidence of diabetes. In 1,253 veterans aged 45–64 years, the 3-year incidence of diabetes (by self-report, FPG ≥ 126 mg/dl or A1C $\geq 7.0\%$) at baseline A1C levels of ≤ 5.5 , 5.6–6.0, and 6.1–6.9% was 0.8, 2.5, and 7.8 per 100 person-years, respectively (8). In 2,820 French people aged 30–65 years whose baseline A1C levels were split into deciles, the 6-year incidence of diabetes (diabetes drugs or FPG ≥ 126 mg/dl) was ~ 2.5 , 5.0, and 10% in the upper three A1C deciles of 5.7, 5.8, and 5.8–7.1%, respectively (9).

Based on the results of these studies relating A1C levels to both prevalent and incident diabetes, an A1C value in a DCCT (Diabetes Control and Complications Trial)-standardized assay (10) of $\geq 5.8\%$ could effectively serve to identify individuals in whom further investiga-

From ¹Charles R. Drew University, Los Angeles, California; and the ²David Geffen School at University of California, Los Angeles, California.

Address correspondence and reprint requests to Mayer B. Davidson, MD, Clinical Center for Research Excellence, Charles R. Drew University, 1731 East 120th St., Los Angeles, CA 90059. E-mail: mayerdavidson@cdrewu.edu.

Received for publication 23 March 2007 and accepted in revised form 2 June 2007.

Published ahead of print at <http://care.diabetesjournals.org> on 11 June 2007. DOI: 10.2337/dc07-0585.

*Student research thesis required for medical school graduation.

Abbreviations: FPG, fasting plasma glucose; HPLC, high-performance liquid chromatography; NHANES, National Health and Nutrition Examination Survey; ROC, receiver operating characteristic.

A table elsewhere in this issue shows conventional and Système International (SI) units and conversion factors for many substances.

© 2007 by the American Diabetes Association.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.




Figure 1—ROC curve for A1C levels to screen for diabetes (defined as an FPG ≥ 126 mg/dl).

tions might be fruitful. Since fasting is not necessary for A1C measurements, this approach would markedly reduce the number of people required to return for a fasting test. Given the A1C result, both physicians and their patients might be more motivated to further explore the potential diagnosis of diabetes.

Alternatively, an argument can be made to utilize only A1C levels for the diagnosis of pre-diabetes/diabetes. The levels of glycemia that are associated with the microvascular complications of diabetes are generally agreed upon as appropriate diagnostic criteria (11). In both type 1 (12–14) and type 2 (15,16) diabetic patients, these complications did not develop or progress for 6–9 years when the average A1C level was kept at $< 7.0\%$. Supporting this relationship, when A1C levels in three large diabetic populations were divided into deciles, the mean value in the first decile, in which retinopathy increased, ranged from 6.7 to 7.5% (17). Regarding A1C levels and pre-diabetes, people in the DPP (Diabetes Prevention Program) (18) with values of 6.1–6.9% were twice as likely to progress to diabetes as those with lower values (19).

Thus, we propose that individuals with A1C levels measured in a DCCT-

standardized assay of $\leq 6.0\%$ are normal, 6.1–6.9% have pre-diabetes, and $\geq 7.0\%$ have diabetes. Since metformin is recommended for those with type 2 diabetes (20) and in younger obese people with pre-diabetes (19), A1C levels should be confirmed in these patients. Alternatively, an A1C level of $\geq 5.8\%$ could lead to a glucose measurement (an FPG or even an oral glucose tolerance test). In either approach, diabetes will be diagnosed in those at clear risk for microvascular complications. Those with pre-diabetes will be identified so that appropriate measures can be adopted to reduce their chances of developing diabetes.

Acknowledgments—M.B.D. was supported by National Institutes of Health (NIH) Grant RR014616. D.K. was supported by NIH Grants RR011145, RR019234, and MD000182.

C.B. acknowledges Curt Rohlfing, BES, for his study model and Shahrzad Bazargan, PhD, for her guidance and support.

References

1. Cowie CC, Rust KF, Byrd-Holt DD, Eberhardt MS, Flegal KM, Engelgau MM, Saydah SH, Williams DE, Geiss LS, Gregg EW: Prevalence of diabetes and impaired

fasting glucose in adults in the U.S. population: National Health and Nutrition Survey 1999–2002. *Diabetes Care* 29: 1263–1268, 2006

2. Harris MI: Undiagnosed NIDDM: clinical and public health issues. *Diabetes Care* 16: 642–652, 1993
3. American Diabetes Association: Clinical Practice Recommendations 2007. *Diabetes Care* 30 (Suppl. 1):S4–S41, 2007
4. Ealovega MW, Tabei B, Brandle M, Burke R, Herman WH: Opportunistic screening for diabetes in routine clinical practice. *Diabetes Care* 27:9–12, 2004
5. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Health Statistics: *Reference Manuals and Reports: Analytic and Reporting Guidelines, 1999–2000*. Hyattsville, MD, National Center for Health Statistics
6. National Health and Nutrition Examination Survey: NHANES 2003–2004 data documentation laboratory assessment: lab 10: glycohemoglobin: years of coverage 2003–2004. In *Documentation, Codebook, and Frequencies: MEC Laboratory Component: Glycohemoglobin: survey years 2003–2004*. Hyattsville, MD, National Center for Health Statistics
7. Rohlfing CL, Little RR, Wiedmeyer HM, England J, Madsen R, Harris MI, Flegal KM, Eberhardt MS, Goldstein DE: Use of GHb (HbA_{1c}) in screening for undiag-

- nosed diabetes in the U.S. population. *Diabetes Care* 23:187–191, 2000
8. Edelman D, Olsen MK, Dudley TK, Harris AC, Oddone EZ: Utility of hemoglobin A1c in predicting diabetes risk. *J Gen Intern Med* 19:1175–1180, 2004
 9. Droumaguet C, Balkau B, Simon D, Caces E, Tichet J, Carles MA, Eschwege E: the DESIR Group: Use of A1C in predicting progression to diabetes in French men and women: data from an Epidemiological Study on the Insulin Resistance syndrome (DESIR). *Diabetes Care* 29:1619–1625, 2006
 10. National Glycohemoglobin Standardization Program [Web site]. Available at <http://www.ngsp.org>.
 11. National Diabetes Data Group: Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. *Diabetes* 28:1039–1057, 1979
 12. Skyler JS: Diabetic complications: the importance of control. *Endocrinol Metab Clin North Am* 25:243–254, 1996
 13. Krolewski AS, Laffel LMB, Krolewski M, Quinn M, Warram JH: Glycosylated hemoglobin and the risk of microalbuminuria in patients with insulin-dependent diabetes mellitus. *N Engl J Med* 332:1251–1255, 1995
 14. Warram JH, Scott LJ, Hanna LS, Wantman M, Cohen SE, Laffel LMB, Ryan L, Krolewski A: Progression of microalbuminuria to proteinuria in type 1 diabetes: nonlinear relationship with hyperglycemia. *Diabetes* 49:94–100, 2000
 15. Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, Kojima Y, Furuyoshi N, Shichiri M: Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. *Diabetes Res Clin Pract* 28:103–117, 1995
 16. Tanaka Y, Atsumi Y, Matsuoka K, Onuma T, Tohjima T, Kawamori R: Role of glyce-mic control and blood pressure in the development and progression of nephropathy in elderly Japanese NIDDM patients. *Diabetes Care* 21:116–120, 1998
 17. Davidson MB, Schriger DL, Peters AL, Lorber B: Relationship between fasting plasma glucose and glycosylated hemoglobin: potential for false-positive diagnoses of type 2 diabetes using new diagnostic criteria. *JAMA* 281:1203–1210, 1999
 18. Diabetes Prevention Program Research Group: Reduction in the incidence of type diabetes with lifestyle intervention or metformin. *N Engl J Med* 346:393–403, 2002
 19. Nathan DM, Davidson MB, DeFronzo RA, Heine RJ, Henry RR, Pratley R, Zinman B: Impaired fasting glucose and impaired glucose tolerance: implications for care. *Diabetes Care* 30:753–759, 2007
 20. Nathan DM, Buse JB, Davidson MB, Heine RJ, Holman RR, Sherwin R, Zinman B: Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. *Diabetes Care* 29:1963–1972, 2006